Safety and tolerability of a modified filter-type device for leukocytapheresis using ACD-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study

Journal of Clinical Apheresis

Volumn 25, Issue 5, 2010, Pages 287-293

  Muratov, Vladislaw ^a   Lundahl, Joachim ^a   Mandic Havelka, Aleksandra ^a   Elvin, Kerstin ^a   Öst, Åke ^b   Shizume, Yasumasa ^c   Furuya, Kaoru ^c   Löfberg, Robert ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Depatment of Clinical Pathology   (Sweden)

^c Asahi Kasei Medical Co   (Germany)

^d Sophiahemmet AB   (Sweden)

Author keywords

apheresis system lines; filter; leukocytapheresis; LL 37; ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ANTICOAGULANT AGENT; BALSALAZIDE; BRADYKININ; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CITRIC ACID; INTERLEUKIN 6; MESALAZINE; SALAZOSULFAPYRIDINE; ACID CITRATE DEXTROSE; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE BINDING PROTEIN; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; CD30 LIGAND; DRUG DERIVATIVE; GLUCOSE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEVICE SAFETY; FEMALE; FILTER; HUMAN; LEUKAPHERESIS; LEUKOCYTE COUNT; MALE; THROMBOCYTE COUNT; TREATMENT OUTCOME; ULCERATIVE COLITIS; ADOLESCENT; BLOOD; INSTRUMENTATION; MIDDLE AGED; PILOT STUDY; SAFETY;

ADOLESCENT; ADULT; ANTICOAGULANTS; ANTIMICROBIAL CATIONIC PEPTIDES; CD30 LIGAND; CITRIC ACID; COLITIS, ULCERATIVE; FEMALE; GLUCOSE; HUMANS; LEUKAPHERESIS; MALE; MIDDLE AGED; PILOT PROJECTS; SAFETY;

EID: 79952199706     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20255     Document Type: Article

References (36)

1. Andoh A, Ogawa A, Kitamura K, Inatomi O, Fujino S, Tsujikawa T, Sasaki M, Mitsuyama K, Fujiyama Y,. Suppression of interleukin-1beta- and tumour necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J Gastroenterol 2004; 39: 1150-1157. (Pubitemid 40074280)
2. Andoh A, Tsujikawa T, Inatomi O, Deguchi Y, Sasaki M, Obata H, Mitsuyama K, Fujiyama Y,. Leukocytapheresis therapy modulates circulating T cell subsets in patients with ulcerative colitis. Ther Apher Dial 2005; 9: 270-276. (Pubitemid 41099515)
3. Muratov V, Ulfgren A-K, Engström M, Elvin K, Winqvist O, Löfberg R, Lundahl J,. Decreased numbers of FoxP3 positive and TLR-2 positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis. J Gastroenterol 2008; 43: 277-282. (Pubitemid 351650038)
4. Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Öst A, Hittel N, Saniabadi A, Löfberg R,. Downregulation of interferon-g parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease. A 12-month follow-up study. Int J Colorectal Dis 2006; 21: 493-504. (Pubitemid 44111274)
5. Sawada K, Muto T, Shimoyama T, Satomi M, Sawada T, Nagawa H, Hiwatashi N, Asakura H, Hibi T,. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003; 9: 307-321. (Pubitemid 36131725)
6. Emmrich J, Petermann S, Nowak D, Beutner I, Brock P, Klingel R, Mausfeld-Lafdhiya P, Liebe S, Ramlow W,. Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis-results of a randomized pilot trial. Dig Dis Sci 2007; 52: 2044-2053. (Pubitemid 47246519)
7. Matsumoto T, Andoh A, Okawa K, Ito H, Torii A, Yoshikawa S, Nakaoka R, Okuyama Y, Oshitani N, Nishishita M, Watanabe K, Fukunaga K, Ohnishi K, Kusaka T, Yokoyama Y, Sasaki M, Tsujikawa T, Aoki T, Kusaka T, Takeda Y, Umehara Y, Nakamura S, Fujiyama Y,. Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study. Ther Apher Dial 2008; 12: 484-490.
8. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476. (Pubitemid 41770166)
9. Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR,. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Lever Dis 2005; 37: 282-297; review. (Pubitemid 41070528)
10. Li Q, Sai Y, Kato Y, Muraoka H, Tamai I, Tsuji A,. Transporter-mediated renal handling of nafamostat mesilate. J Pharm Sci 2004; 93: 262-272. (Pubitemid 38174249)
11. Kojima S, Harada-Shiba M, Nomura S, Kimura G, Tsushima M, Kuramochi M, Yamamoto A, Omae T,. Effect of nafamostat mesilate on bradykinin generation during low-density lipoprotein apheresis using a dextran sulfate cellulose column. ASAIO Trans 1991; 37: 644-648.
12. Iwama H,. Bradykinin-associated reactions in white cell-reduction filter. J Crit Care 2001; 16: 74-81. (Pubitemid 32729944)
13. Hild M, Söderström T, Egberg N, Lundahl J,. Kinetics of bradykinin levels during and after leucocyte filtration of platelet concentrates. Vox Sang 1998; 75: 18-25. (Pubitemid 28432797)
14. Schaefer RM, Fink E, Schaefer L, Barkhausen R, Kulzer P, Heidland A,. Role of bradykinin in anaphylactoid reactions during hemodialysis with AN69 dialyzers. Am J Nephrol 1993; 13: 473-477. (Pubitemid 24041069)
15. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kikuyama M, Tanaka T, Kondo K, Tanaka K, Takai K,. Decrease of reactive-oxygen-producing granulocytes and release of IL-10 into the peripheral blood following leukocytapheresis in patients with active ulcerative colitis. World J Gastroenterol 2005; 11: 3085-3090. (Pubitemid 40790668)
16. Mitsuyama K, Suzuki A, Matsumoto S, Tomiyasu N, Takaki K, Takedatsu H, Masuda J, Handa K, Harada K, Nishida H, Toyonaga A, Sata M,. Diminished cytokine signalling against bacterial components in mononuclear leukocytes from ulcerative colitis patients after leukocytapheresis. Clin Exp Immunol 2005; 141: 130-140. (Pubitemid 40904650)
17. Kashiwagi N, Sugimura K, Koiwai H, Yamamoto H, Yoshikawa T, Saniabadi AR, Adachi M, Shimoyama T,. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 2002; 47: 1334-1341. (Pubitemid 34606638)
18. + monocytes in leukocytapheresis therapy for ulcerative colitis. Inflamm Bowel Dis 2007; 13: 284-290. (Pubitemid 46465909)
19. Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsishita I, Ivaoka Y, Saniabadi A,. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol 2004; 99: 1532-1538. (Pubitemid 39180103)
20. Tozawa K, Fukunaga K, Kamikozuru K, Ohnishi K, Hida N, Ohda Y, Kusaka T, Yoshida K, Jinno Y, Nagase K, Nakamura S, Miwa H, Matsumoto T,. Hyperthermic stimulation of blood increases the immunological effects of granulocyte and monocyte adsorption in vitro: relevance to extracorporeal immunomodulation. Transfus Apher Sci 2008; 39: 129-135.
21. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH,. Use of the non-invasive components of the mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008; 14: 1660-1666.
22. Geboes K, Riddel R, Öst Å, Jensfelt B, Persson T, Löfberg R,. A reproducible grading for histological assessment of inflammation in ulcerative colotis. Gut 2000; 47: 404-409.
23. Osada T, Ohkusa T, Okayasu I, Yoshida T, Hirai S, Beppu K, Shibuya T, Sakamoto N, Kobayashi O, Nagahara A, Terai T, Watanabe S,. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol 2008; 23: 262-267.
24. Sun X, Somada S, Shibata K, Muta H, Yamada H, Yoshihara H, Honda K, Nakamura K, Takayanaqi R, Tani K, Podack R, Yoshikai Y,. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice. Gastroenterology 2008; 134: 447-458.
25. Davidson DJ, Currie AJ, Reid GS, Bowdish DM, MacDonald KL, Ma RC, Hancock RE, Speert DP,. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol 2004; 172: 1146-1156. (Pubitemid 38113775)
26. Akashi-Takamura S, Miyake K,. TLR accessory molecules. Curr Opin Immunol 2008; 20: 420-425.
27. Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, Shimoyama T,. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005; 100: 1362-1369. (Pubitemid 40904363)
28. Chuang CM, Monie A, Wu A, Mao CP, Hung CF,. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther 2009; 20: 303-313.
29. Bergman P, Walter-Jallow L, Broliden K, Agerberth B, Söderlund J,. The antimicrobial peptide LL-37 inhibits HIV-1 replication. Curr HIV Res 2007; 5: 410-415. (Pubitemid 47040482)
30. Ouhara K, Komatsuzawa H, Yamada S, Shiba H, Fujiwara T, Ohara M, Sayama K, Hashimoto K, Kurihara H, Sugai M,. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, ß-defensins and LL37, produced by human epithelial cells. J Antimicrob Chemother 2005; 55: 888-896. (Pubitemid 40883173)
31. Komatsuzawa H, Ouhara K, Yamada S, Fujiwara T, Sayama K, Hashimoto K, Sugai MJ,. Innate defences against methicillin-resistant Staphylococcus aureus (MRSA) infection. Pathology 2006; 208: 249-260; review. (Pubitemid 43126117)
32. Wehlin L, Gustavsson K, Halldén G, Emilson A, Svensson A, Hild M, Lundahl J,. Complement activation during blood sampling procedures alters the expression of CD11b/CD18 on human neutrophils. Vox Sang 1998; 74: 21-26. (Pubitemid 28033376)
33. Borregaard N, Kjeldsen L, Sengløv H, Diamond MS, Springer TA, Anderson HC, Kishimoto TK, Bainton DF,. Changes in subcellular localization and surface expression of L-selectin, alkaline phosphatase, and Mac-1 in human neutrophils during stimulation with inflammatory mediators. J Leukoc Biol 1994; 56: 80-87. (Pubitemid 24241786)
34. Sørensen O, Arnljots K, Cowland JB, Bainton DF, Borregaard N,. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 1997; 90: 2796-2803. (Pubitemid 27413490)
35. Mookherjee N, Brown KL, Bowdish DM, Doria S, Falsafi R, Hokamp K, Roche FM, Mu R, Doho GH, Pistolic J, Powers JP, Bryan J, Brinkman FS, Hancock RE,. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 2006; 176: 2455-2464. (Pubitemid 43201696)
36. Ohkusa T, Nomura T, Sato N,. The role of bacterial infection in the pathogenesis of inflammatory bowel disease. Intern Med 2004; 43: 534-539. (Pubitemid 39206689)